Caption Management, LLC 89bio, Inc. Put Options Transaction History

Caption Management, LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	BUY	$4.83 - $10.57 $1.49 Million - $3.26 Million	308,800 Added 86.55%	665,600 $6.54 Million
Q1 2025 May 15, 2025	SELL	$6.18 - $11.66 $465,354 - $877,998	-75,300 Reduced 17.43%	356,800 $2.59 Million
Q4 2024 Feb 14, 2025	SELL	$7.03 - $10.05 $234,802 - $335,670	-33,400 Reduced 7.18%	432,100 $3.31 Million
Q3 2024 Nov 14, 2024	SELL	$7.36 - $9.66 $69,184 - $90,804	-9,400 Reduced 1.98%	465,500 $3.44 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $3.16 Million - $7.61 Million	474,900 New	474,900 $5.3 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $3.7 Million - $5.99 Million	353,500 New	353,500 $5.38 Million

212

161M

299K

1.61M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $688M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.